TDA RESEARCH, INC. — Department of Defense SBIR Phase II: DHA PHASE II SBIR CONTRACT FOR PSORALEN-UV-A INACTIVATION BASED HIGH-THROUGHPUT PATHOGEN I
TDA RESEARCH, INC. — SBIR Phase II award from Department of Defense.
Phase II SBIR prototype / development signal
- Phase II is where Department of Defense funds deeper R&D after feasibility. Incumbents with Phase II history are serious competitors on adjacent topics.
- Use this award as past-performance context and to map customer organizations for STRATFI/TACFI-style transition planning.
- Obligated amount $1,299,966 is consistent with substantial Phase II-scale effort; compare to related awards from the same agency.
- Tagged technology areas: Human Performance & Medical. Follow those hubs for open topics and peer winners in the same cluster.
Summary
TDA Research, Inc. was awarded about $1.3 million under a DoD SBIR Phase II contract to develop a high-throughput device that uses Psoralen-UV-A technology to inactivate pathogens. The goal is to create a practical medical tool that improves safety by removing harmful microorganisms from blood or other fluids.
- Amount
- $1,299,966
- Agency
- Department of Defense · Defense Health Agency
- Program / Phase
- SBIR · Phase II
- NAICS
- 541715 · RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT NANOTECHNOLOGY AND BIOTECHNOLOGY)
- Place of performance
- CO
- Period
- 2025-07-11 → 2027-11-10
Technology domains
Description
DHA PHASE II SBIR CONTRACT FOR PSORALEN-UV-A INACTIVATION BASED HIGH-THROUGHPUT PATHOGEN INACTIVATION DEVICE